Related Experiment Video
Updated: Aug 10, 2026

Testing the Efficacy of Pharmacological Agents in a Pericardial Target Delivery Model in the Swine
Published on: July 7, 2016
Disopyramide: clinical indications, pharmacokinetics and laboratory assessment
Abstract:
Disopyramide is an antiarrhythmic drug similar to quinidine and used primarily to treat ventricular ectopic systoles. Unlike quinidine which shows drug-drug interaction with digoxin, disopyramide appears to be free of this problem. Side effects include anticholinergic symptoms, cardiovascular problems, and some gastrointestinal discomfort. Disopyramide is metabolized to N-desisopropyl disopyramide in the liver with approximately 50 percent of the parent drug excreted unchanged. The elimination half-life varies from 4.5 to nine hours, and it can be even longer in cases of renal failure or myocardial infarction. There exists an extremely variable degree of protein binding (10 to 70 percent), which is highly dependent on concentration. The unbound (free) fraction increases with increasing drug concentration, making the interpretation of total disopyramide concentrations very difficult. Since the free drug concentration is more representative of availability to its receptor, and only the free fraction is available for renal excretion, the free drug concentration may represent a better predictor of therapeutic effectiveness. Methods for determining concentrations of disopyramide include gas chromatography, high performance liquid chromatography, homogeneous enzyme immunoassay (EMIT), and fluorescence polarization immunoassay. A method for performing both total and free disopyramide determinations is also described.
More Related Videos
07:42Contractions of Human-iPSC-derived Cardiomyocyte Syncytia Measured with a Ca-sensitive Fluorescent Dye in Temperature-controlled 384-well Plates
Published on: October 18, 2018
10:41Laser-Induced Action Potential-Like Measurements of Cardiomyocytes on Microelectrode Arrays for Increased Predictivity of Safety Pharmacology
Published on: September 13, 2022
Related Concept Videos
Depolarizing Blockers: Pharmocokinetics
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Dysrhythmias V: Evaluating Dysrhythmias